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Abstract: Spinal muscular atrophy (SMA) is a neurodegenerative disease produced by low 
levels of Survival Motor Neuron (SMN) protein that affects alpha motoneurons in the 
spinal cord. Notch signaling is a cell-cell communication system well known as a master 
regulator of neural development, but also with important roles in the adult central nervous 
system. Aberrant Notch function is associated with several developmental neurological 
disorders; however, the potential implication of the Notch pathway in SMA pathogenesis 
has not been studied yet. We report here that SMN deficiency, induced in the astroglioma 
cell line U87MG after lentiviral transduction with a shSMN construct, was associated with 
an increase in the expression of the main components of Notch signaling pathway, namely 
its ligands, Jagged1 and Delta1, the Notch receptor and its active intracellular form 
(NICD). In the SMNΔ7 mouse model of SMA we also found increased astrocyte processes 
positive for Jagged1 and Delta1 in intimate contact with lumbar spinal cord motoneurons. 
In these motoneurons an increased Notch signaling was found, as denoted by increased 
NICD levels and reduced expression of the proneural gene neurogenin 3, whose 
transcription is negatively regulated by Notch. Together, these findings may be relevant to 
understand some pathologic attributes of SMA motoneurons. 
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1. Introduction 
Spinal muscular atrophy (SMA) is a neurodegenerative disease inherited in an autosomal recessive 
manner that affects alpha motoneurons in the spinal cord, and causes muscular atrophy of proximal 
limb and trunk muscles, paralysis, and in the most severe cases, death [1,2]. SMA is caused by the 
homozygous deletion or specific mutations of the Survival Motor Neuron 1 (SMN1) gene, which 
results in reduced dosage of full-length SMN protein [3]. The deletion of SMN1 homologs in other 
animals is lethal at early embryonic ages [4]; however, the human genome contains a variable number 
of copies of the SMN2 gene that produces about 90% of a highly unstable, truncated protein, called 
SMNΔ7 due to defective mRNA maturation, and only 10% of normal (full-length) protein [5]. Thus, 
the severity of the disease depends on the number of copies of SMN2 gene [6]. 
Notch signaling is a cell-cell communication system well known as a master regulator of neural 
development [7–9]. Four Notch receptors (Notch1–4) and five ligands (Jagged1 and 2; Delta-like1,  
3 and 4) have been identified in mammals [10]. Upon ligand binding, a series of cleavage events 
culminate in the proteolytic cleavage of the transmembrane Notch receptor by the γ-secretase, giving 
rise to the Notch intracellular domain (NICD), which is translocated into the cell nucleus. Canonical 
Notch signaling involves the binding of NICD to DNA-binding cofactors and the subsequent activation 
of the transcription of target genes [11,12]. The most studied Notch targets are the Hairy and Enhancer 
of Split (Hes) genes. Hes1 negatively controls the expression of a series of proneural genes, including 
Neurogenin 3 (Ngn3), involved in neuritogenesis [13–15]. During the development of the central 
nervous system in vertebrates, the nascent neurons, by expressing Delta1, deliver lateral inhibition to 
the Notch1-expressing progenitors in contact with them, so as to prevent these progenitors from 
differentiating prematurely into neurons and from expressing Delta1 [16]. In addition, Notch 
expression persists throughout the adult brain in differentiated cells [17,18]. Aberrant Notch function is 
associated with several developmental neurological disorders and neurodegenerative diseases 
(reviewed by [19]), and increased expression of Notch has been described in Alzheimer’s disease, 
Pick’s disease and Down syndrome [20,21]; however, the potential implication of Notch pathway in 
SMA pathogenesis has not been studied yet. 
Several findings suggest a potential implication of the Notch system in SMA pathology: Notch1 
(hereafter referred to as Notch) as well as SMN share common functions in the regulation of neurite 
outgrowth [13,22–25], cell migration [26,27], axon guidance [28,29] and neuromuscular junction 
maturation [30,31]. In addition, Notch signaling functions in astrocytes as an inducer of characteristic 
elements for reactive gliosis [32,33], and reactive gliosis has also been described in different types of 
human SMA [34–36] and in the ventral spinal cord of SMA mice [37]. In this sense, we hypothesized 
that SMN depletion could be related to an increased activation of the Notch signaling pathway in 
astrocytes. Thus, we first studied in vitro, in the U87MG astroglioma cell line experimentally depleted 
of SMN, the immunoexpression of Notch, its active intracellular domain (NICD) and its ligands 
(Jagged1 and Delta1). Then, in an in vivo model of SMA, the SMNΔ7 mouse model, we also studied 
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the expression of Notch ligands in reactive astrocytes in relation with the potential activation of the 
Notch signaling in the neighboring spinal cord motoneurons. 
2. Results 
2.1. Increased Notch Signaling in U87MG Astroglioma Cells Depleted of SMN 
Four days after lentiviral transduction of U87MG astroglioma cells with an shRNA sequence 
targeting SMN nearly a 60% reduction in SMN expression levels was found by western blotting, as 
compared to those transduced with shRNA EV (Figure 1A,B) and as previously described [27]. Then, 
the expression levels of four participants in the Notch signaling pathway, namely its ligands Jagged1 
and Delta1, the Notch receptor and its active intracellular form (NICD) were studied by western 
blotting. The expression of these proteins was found significantly increased after SMN depletion. The 
Notch ligands Jagged1 and Delta1 increased their expression around five to six fold. The Notch 
receptor increased its expression around two fold, whereas the levels of its active form, NICD were 
found increased around four fold, as compared to shRNA EV (Figure 1A,B). Moreover, by performing 
immunocytochemistry in U87MG cells, increased NICD immunoreactivity was found in the nuclei of 
SMN deficient cells as compared to those transduced with shRNA EV (Figure 1C). 
Together, these results indicated that SMN depletion in an astrocyte cell line was associated to an 
increased activation of the Notch signaling pathway. We therefore studied in an in vivo model, the 
SMNΔ7 mouse, if Notch ligands could also be increased on spinal cord astrocytes, as well as the 
potential effects on neighboring spinal cord motoneurons. 
Figure 1. Activation of Notch pathway in U87MG astroglioma cells by Survival Motor 
Neuron (SMN) depletion. (A) Western blots showing SMN, Jagged1, Delta1, Notch and 
anti-cleaved Notch1 (NICD) immunoreactivities in U87MG cells after transduction with 
lentiviruses containing the empty vector (shRNA EV) or the shSMN constructs, as 
indicated. (B) Column bars indicate the immunoreactivity of each protein as determined by 
densitometric analysis (integrated optical density of each protein band vs. that of α-tubulin 
band), and are the mean ± SEM of three independent experiments. * At least p < 0.01 as 
compared to shRNA EV. (C) Immunocytochemistry showing increased NICD in the nuclei 
of cells transduced with shSMN construct as compared to that transduced with shRNA EV, 
as indicated. Scale bar = 10 μm.  
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2.2. Increased Notch Signaling in Spinal Cord Motoneurons of the SMNΔ7 Mouse 
In the SMNΔ7 mouse model of SMA, motor impairment is manifest at postnatal day 11 (P11) [38]. 
Immunostaining was performed for GFAP to visualize astroglia in the lumbar spinal cord of SMNΔ7 
mice at this postnatal age. Quantification of the relative area of GFAP-positive structures within the 
ventral horn demonstrated a significant increase in this parameter in SMA mutants as compared to WT 
(Figure 2A–C). In SMA astrocytes the expression of the Notch ligands Jagged1 and Delta1 was found 
to be significantly increased (281 and 249 percent of increase; respectively) (Figure 2A,B,D,E). Spinal 
cord motoneurons were identified by their large bodies (>20 μm) when labeled with blue fluorescent 
Neuro Trace Nissl staining (Figure 2A,B). Astroglial processes with strong immunoreactivities for 
Jagged1 and Delta1 were found in intimate contact with motoneurons in SMA (Figure 2A,B, insets). 
Figure 2. Astrocytosis and increased expression of Jagged1 and Delta1 in the ventral 
spinal cord of SMNΔ7 mice. (A,B) Representative images of anti-glial fibrillary acidic 
protein (GFAP) and Jagged1 (A) or GFAP and Delta1 (B) immunohistochemistry in the 
ventral horn of lumbar spinal cord of P11 wild-type (WT) and SMNΔ7 mice. Insets: 
astrocytes processes double labeled with GFAP and Jagged1 in (A) or with GFAP and 
Delta1 in (B) are in close apposition with motoneurons labeled with blue fluorescent Neuro 
Trace Nissl staining. Scale bars in (B) = 20 μm and 10 μm (inset), also apply to (A).  
(C) Columns represent the percentage of GFAP positive area in the ventral horn of lumbar 
spinal cord of P11 SMNΔ7 as compared to control (WT) mice and represent the  
mean ± SEM (error bars) of at least four mice for each group. *** p < 0.001 as compared 
to age-matched WT. (D,E) Columns represent the percentage of Jagged1 (D) or Delta1 (E) 
immunoreactivities in GFAP-positive cells (astrocytes) in the lumbar spinal cord of P11 
SMNΔ7 as compared to control (WT) mice and represent the mean ± SEM (error bars) of 
at least four mice for each group. *** p < 0.001 and ** p < 0.01 as compared to  
age-matched WT. 
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Figure 3. Notch signaling is activated in spinal muscular atrophy (SMA) spinal cord 
motoneurons. (A,B) Representative images of SMI-32 and Notch (A) or SMI-32 and NICD 
(B) immunohistochemistry in the ventral horn of lumbar spinal cord of P11 wild-type 
(WT) and SMNΔ7 mice showing that motoneurons are co-labeled with these antibodies 
(merge), and display increased Notch (A) or NICD (B) expression in SMNΔ7 mice. 
Arrows in (B) indicate the presence of NICD immunoreactivity in the nucleus of SMNΔ7 
motoneurons. Scale bar = 20 μm applies to all photographs in (A) and (B). (C,D) Columns 
represent the percentage of Notch (C) or NICD (D) immunoreactivities in SMI-32 positive 
cells (motoneurons) in the lumbar spinal cord of P11 SMNΔ7 as compared to control (WT) 
mice and represent the mean ± SEM (error bars) of at least four mice for each group.  
*** p < 0.001 as compared to age-matched WT. 
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Activation of Notch receptor is induced via cell to cell contact-mediated binding of its ligands; thus, 
we examined if Notch pathway could be activated in spinal cord motoneurons of SMA mutants. A 
significant increase (215%) in the immunoreactivity of Notch receptor was observed co-localizing with 
that of SMI-32 antibody in lumbar spinal cord motoneurons of SMA mutants, as compared to  
age-matched WT animals (Figure 3A,C). Moreover, a significant increase (308%) in the 
immunoreactivity for NICD was found in SMA motoneurons (Figure 3B,D). Increased levels of NICD 
were detected in the perikaryon but also in the nucleus of these cells (Figure 3B, arrows).  
The activation of Notch signaling in postmitotic neurons results in the inhibition of the expression 
of Ngn3 [13]. Thus, to further test Notch signaling activation in SMA motoneurons, Ngn3 levels were 
studied in these cells. Ngn3 immunoreactivity was found to be located both in the nucleus and 
perikaryon of spinal cord motoneurons in WT mice (Figure 4A), by contrast, a significant reduction 
(54%) of Ngn3 immunoreactivity in motoneurons of SMA mutants was found, with absence of Ngn3 
in their nuclei (Figure 4A,B). Thus, SMA motoneurons show increased NICD levels and reduced Ngn3 
expression, confirming the activation of the Notch pathway in these cells. 
Figure 4. Decreased neurogenin 3 (Ngn3) expression in SMA spinal cord motoneurons.  
(A) Representative images of SMI-32 and Ngn3 immunohistochemistry in the ventral horn 
of lumbar spinal cord of P11 wild-type (WT) and SMNΔ7 mice showing that motoneurons 
are co-labeled with these antibodies (merge), and display decreased Ngn3 expression in 
SMNΔ7 mice. Arrows point to the nuclei of motoneurons to indicate the lack of Ngn3 
immunoreactivity in SMNΔ7 mouse. Scale bar = 20 μm applies to all photographs in (A). 
(B) Columns represent the percentage of Ngn3 immunoreactivity in SMI-32 positive cells 
(motoneurons) in the lumbar spinal cord of P11 SMNΔ7 as compared to control (WT) mice 
and represent the mean ± SEM (error bars) of at least four mice for each group. *** p < 0.001 
as compared to age-matched WT. 
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3. Discussion  
SMN deficiency induced in vitro in the astroglioma cell line U87MG resulted in an increase in the 
expression of the main components of Notch signaling pathway, as well as increased localization of 
NICD in cell nuclei. These results prompted us to explore in the SMNΔ7 mouse model of SMA the 
expression of Notch ligands in reactive astrocytes, and the potential activation of the Notch signaling 
in the neighboring spinal cord motoneurons. 
Our results, indicating astrocytosis in the lumbar spinal cord of SMNΔ7 mice at P11, are in 
agreement with previous findings in which, in a more severe mouse model of SMA, ventral horn 
astrocytosis was detectable before and during spinal cord motoneuron death [37]. Interestingly, 
motoneuron loss has also been reported in the lumbar spinal cord of the SMNΔ7 mice at symptomatic 
stages [38]; thus, astroglial activation in SMNΔ7 mice may be associated with motoneuron pathology, 
as previously described in amyotrophic lateral sclerosis [39]. How reactive astrocytes affect motoneuron 
function in SMA has not been studied yet. Here, we report that reactive astrocytes in SMA display 
increased expression of the Notch ligands Jagged1 and Delta1. Although in vitro SMN depletion 
induced increased expression of Notch ligands in U87MG cells, suggesting a potential role of SMN as 
a repressor of Notch ligands expression in astrocytes, the mechanisms that regulate their expression  
in vivo in mature astrocytes are not fully understood. In this sense, the expression of Jagged1 is 
increased in astrocytes under an inflammatory environment [32] and it has been proposed the 
involvement of inflammatory pathways in SMA [40]. Moreover, the cytokine transforming growth 
factor β1 (TGFβ1) is directly implicated in the up-regulation of Jagged1 expression in astrocytes [41]; 
interestingly, disruption of TGFβ signaling is an important molecular event in the pathogenesis of several 
motoneuron diseases [42]. In addition, Jagged1 has an important role promoting astrocytosis [43] 
through the induction of GFAP gene expression [32]; thus, it can be proposed that the observed 
increase in GFAP immunoreactivity in the ventral horn of our SMA mutants may be also a result of the 
increased expression of Jagged1 in astrocytes. 
It has been demonstrated that Jagged1 induces Notch signaling in adjacent cells through a  
cell-to-cell relay [44]. As astrocyte processes expressing high levels of Notch ligands were observed in 
intimate contact with spinal cord motoneurons, we addressed if the Notch pathway could be activated 
in these cells. Immunoreactivity for the active form of Notch (NICD) was found increased both in the 
nucleus and perikaryon of motoneurons from SMNΔ7 mice, demonstrating an activation of Notch 
signaling in SMA motoneurons. A similar pattern of NICD distribution has been described in 
hippocampal neurons in response to activity; in these cells a parallel increase in Notch receptor 
expression was also reported [45]. In agreement with these findings, we also found an increase in 
Notch receptor expression in SMA motoneurons. As NICD is a relatively unstable fragment of  
Notch [46], it has been proposed that positive feedback loops occur in Notch system in which Notch 
ligands maintain increased Notch receptor expression in cells undergoing Notch signaling [44,47]. 
Thus, our results suggest that SMN depletion in vitro in an astroglioma cell line, and in vivo in the 
SMNΔ7 mouse is associated to an increased expression of Notch ligands in astrocytes and that these 
cells may activate Notch signaling in adjacent motoneurons. 
Ngn3 is a protein whose expression is negatively regulated by Notch signaling [13–15]. Our results 
demonstrating reduced Ngn3 expression in SMA motoneurons further indicate that Notch signaling is 
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abnormally active in these cells. In WT motoneurons Ngn3 immunoreactivity was found both in the 
perikaryon and the cell nucleus. Previous studies have shown that Ngn3 immunoreactivity is also 
located in the perikaryon and neurites of hippocampal neurons, however, during the differentiation 
process its immunoreactivity progressively increases in the nucleus [48]. As Ngn3 functions as a 
transcriptional regulator, our results indicating a total absence of Ngn3 immunoreactivity in the nucleus of 
SMA motoneurons arise important repercussions in the context of SMA pathogenesis. Ngn3 has been 
demonstrated to promote neurite outgrowth [13]. In this sense, lack of axonal outgrowth has been 
described in some spinal cord motoneurons of human SMA [49] and, in murine models, it has been 
reported an important denervation of some muscles (up to 50% in intercostal muscles), together with a 
functional deficit and arrest of postnatal development of neuromuscular junctions, showing clusters of 
unoccupied acetylcholine receptors [31,50]. These findings indicate that impairment/lack of motor 
nerve terminals in SMA could be related to Ngn3 deficit in spinal cord motoneurons. In PC-12 cells, 
SMN deficiency also resulted in neuritogenesis impairment in NGF-differentiated cells; however, the 
effect was related to an up-regulation of the RhoA/ROCK pathway [23]. Also, we reported that in 
U87MG cells SMN deficiency resulted in impaired cell migration by altering actin cytoskeleton 
through the activation of RhoA/ROCK [27]. Interestingly, Notch signaling has also been found to 
activate this pathway to regulate actin dynamics [51] and thus, to inhibit neurite extension [52]. In 
addition to an impaired neuritogenesis, increased Notch activation in spinal cord motoneurons may 
predispose them to apoptosis, as demonstrated in cortical neurons in response to ischemic stroke [53].  
Besides to its roles in neurons and astroglia, Notch has profound functions in other cell types in the 
brain, including microglia [54], oligodendrocytes [55] and endothelial cells [56]; thus, further studies 
are needed towards understanding the role of Notch system in SMA. 
4. Experimental Section 
4.1. U87MG Cell Culture and Transduction 
U87MG human astroglioma cells were a gift from Dr. Priam Villalonga (IUNICS, University of the 
Balearic Islands, Palma de Mallorca, Spain). U87MG cells were subconfluently grown and passaged, 
routinely tested for mycoplasma contamination and subjected to frequent morphological tests and growth 
curve analysis as quality-control assessments. U87MG cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 2 mM L-glutamine and 5% heat-inactivated fetal calf serum in a 
humidified incubator at 37 °C with 5% CO2.  
To reduce SMN expression, RNA interference experiments were employed using lentiviral 
particles, as previously described [27]. Briefly, constructs were generated in pSUPER.retro.puro 
(OligoEngine; Seattle, WA, USA) using specific oligonucleotides targeting SMN  
sequence, indicated by capital letters and as previously described [57]; forward: 
gatccccCGACCTGTGAAGTAGCTAAttcaagagaTTAGCTACTTCACAGGTCGttttt and reverse: 
agctaaaaaCGACCTGTGAAGTAGCTAAtctcttgaaTTAGCTACTTCACAGGTCGggg. For lentiviral 
transduction, cells were plated at a density of 25,000 cells/mL in 6-well plates and 3 h later medium 
was replaced with medium containing lentiviruses (2 TU/cell) carrying shRNA empty vector (EV) or 
shSMN. The medium was replaced with fresh medium 24 h later and infection efficiency was monitored in 
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each experiment by direct counting Green Fluorescent Protein (GFP)-positive cells. Cells were grown 
for 4 additional days before sample collection for western blotting or immunocytochemistry assays.  
4.2. Western Blotting 
U87MG cells were rinsed in ice-cold PBS and lysed with 50 mM Tris HCl, pH 6.8, 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100 containing a cocktail of protease inhibitors (Complete Mini; Roche 
Pharmaceutical, Basel, Switzerland). Lysates were sonicated and proteins quantified by means of the 
DC Protein Assay from Bio-Rad Laboratories (Hercules, CA, USA). Protein equivalents from each 
sample were resolved in SDS-polyacrilamide gel electrophoresis and electrotransferred to 0.45 µm 
nitrocellulose membranes (Amersham; Buckinghamshire, UK) using a Bio-Rad semidry trans-blot, 
according to the manufacturer’s instructions. Membranes were blocked at 21 ± 1 °C for 1 h with PBS 
containing non-fat dry milk, 0.5% bovine serum albumin (BSA) and 0.2% Tween 20. Membranes were 
probed overnight at 4 °C using antibodies directed to SMN (1:5000) from BD Biosciences  
(Franklin Lakes, NJ, USA); Jagged1 (1:1000) and Delta1 (1:500) both from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA); Notch and NICD (1:1000) both from Cell Signaling Technology (Danvers, 
MA, USA) and α-tubulin, (1:5000) from Sigma-Aldrich (St. Louis, MO, USA). Membranes were then 
washed with PBS and incubated for 2 h with the appropriate peroxidase-conjugated secondary 
antibody. Blots were developed with the chemiluminescent peroxidase substrate and visualized in 
chemiluminescence film (Amersham). The apparent molecular weight of proteins was determined by 
calibrating the blots with pre-stained molecular weight markers (Bio-Rad). 
4.3. Mouse Model 
Mouse lines were kindly provided by Dr. A. Burghes (The Ohio State University, Columbus, OH, 
USA). Experimental mice were obtained by breeding pairs of SMA carrier mice (Smn+/−; SMN2+/+; 
SMN∆7+/+) on a FVB/N background. Identification of wild-type (WT) (Smn+/+; SMN2; SMN∆7) and 
mutant SMA mice (Smn−/−; SMN2; SMN∆7) was done by PCR genotyping of tail DNA as previously 
described [31,38]. WT and mutants mice were always used at P11. All experiments were performed 
according to the guidelines of the European Communities Council Directive for the Care of  
Laboratory Animals. 
4.4. Immunofluorescence and Nissl Staining 
Mice were anesthetized with 2% tribromoethanol (0.15 mL/10 g body weight, i.p.) and 
intracardiacally perfused with saline solution followed by 4% paraformaldehyde in 0.1 M phosphate 
buffer, pH 7.4. Spinal cords were post-fixed by immersion in the same fixative solution for 1–24 h. 
Then, transverse serial cryostat sections (10 μm thick) from lumbar segments were obtained with a 
Leica cryostat (Leica CM3050) and mounted on microscope slides. Sections were quenched with 3% 
H2O2 in phosphate buffer saline (PBS) and permeabilized with methanol for 5 min. Then, sections 
were blocked with 5% normal goat serum and 0.2% Triton X-100 in PBS for 1 h. Sections were 
incubated overnight at 4 °C with the primary antibody diluted in blocking solution. The following 
primary antibodies were used for immunofluorescence: anti-glial fibrillary acidic protein (GFAP) 
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(1:1000) from Dako Cytomation (Glostrup, Denmark); anti-Jagged1 (1:200) and anti-Delta1 (1:200) 
from Santa Cruz Biotechnology; anti-Notch (1:200) from Cell Signaling Technology; anti-cleaved 
Notch1 (NICD) (1:200) from Santa Cruz Biotechnology; anti-neurofilament heavy chain (SMI-32, 
1:1000) from Sternberger Monoclonals Inc. (Baltimore, MD, USA) and anti-neurogenin 3 (Ngn3) 
(1:200) from Millipore (Temecula, CA, USA). The SMI-32 antibody was used to specifically label 
spinal cord motoneurons as previously described [58].  
For immunofluorescence, sections were incubated for 1 h with the appropriate secondary antibody, 
Alexa Fluor 555 goat anti-mouse IgG (1:200) or Alexa Fluor 488 goat anti-rabbit IgG (1:200) 
(Invitrogen, Carlsbad, CA, USA). Sections were then washed and mounted using Fluorescent Mounting 
Medium (Dako Cytomation). Immunohistochemical controls, performed by omitting the primary 
antibody, resulted in the abolition of the immunostaining. In some cases, spinal cord sections were also 
labeled with blue fluorescent Neuro Trace Nissl staining (Molecular Probes, Eugene, OR, USA). 
4.5. Image Acquisition and Analysis 
Images were acquired digitally using a 20× or 40× oil immersion objective with a Leica TCS SP2 
confocal laser-scanning microscope. Images from WT and SMA mutant littermate preparations were 
taken with similar conditions (laser intensities and photomultiplier voltages). A minimum of ten 
lumbar spinal cord sections were studied for animal and experimental situation, with at least four mice 
for each experimental condition. In order to quantify GFAP immunoreactivity four selected fields of 
ventral spinal cord were digitized and the Mean Gray Value for GFAP immunoreactivity was 
measured in a blinded manner and corrected by the value of the area of the field to obtain the relative 
GFAP positive area. In order to quantify Jagged1, Delta1, Notch, NICD or Ngn3 immunoreactivities, 
four selected fields of ventral spinal cords containing cells labeled with anti-GFAP or SMI32 
antibodies were digitized and the Mean Gray Value for Jagged1 or Delta1 immunoreactivity in  
GFAP-positive cells (astrocytes) as well as Notch, NICD or Ngn3 immunoreactivity in SMI32-positive 
cells (motoneurons) were measured in a blinded manner with ImageJ (W. Rasband, National Institutes 
of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/). The values were background subtracted using the 
average Mean Gray Value of the preparation background in each of the experimental conditions and 
data were always represented as a percentage of the values in WT mice. 
4.6. Statistical Analysis 
All data are expressed as mean ± SEM values. Statistical significance was assessed by Student’s  
t-test. Differences were considered significant when the p value was less than 0.05. 
5. Conclusions 
In summary, our results demonstrate that, both in vitro and in vivo, SMN deficiency results in 
increased expression of Notch ligands on astrocytes and that lumbar spinal cord motoneurons of 
SMNΔ7 mice, adjacent to reactive astrocytes, display increased Notch signaling, as denoted by 
increased NICD levels and reduced expression of the proneural gene Ngn3. These findings may be 
relevant to understand some pathologic attributes of SMA motoneurons.  
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